99 related articles for article (PubMed ID: 21194833)
1. Enzyme prodrug therapy designed to target L-methioninase to the tumor vasculature.
Van Rite BD; Lazrak YA; Pagnon ML; Palwai NR; Neves LF; McFetridge PS; Harrison RG
Cancer Lett; 2011 Feb; 301(2):177-84. PubMed ID: 21194833
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of an enzyme prodrug therapy targeted to the breast tumor vasculature.
Van Rite BD; Krais JJ; Cherry M; Sikavitsas VI; Kurkjian C; Harrison RG
Cancer Invest; 2013 Oct; 31(8):505-10. PubMed ID: 24083814
[TBL] [Abstract][Full Text] [Related]
3. Annexin V-Directed Enzyme Prodrug Therapy Plus Docetaxel for the Targeted Treatment of Pancreatic Cancer.
Guillen KP; Restuccia A; Kurkjian C; Harrison RG
Pancreas; 2015 Aug; 44(6):945-52. PubMed ID: 25899647
[TBL] [Abstract][Full Text] [Related]
4. Methioninase cancer gene therapy with selenomethionine as suicide prodrug substrate.
Miki K; Xu M; Gupta A; Ba Y; Tan Y; Al-Refaie W; Bouvet M; Makuuchi M; Moossa AR; Hoffman RM
Cancer Res; 2001 Sep; 61(18):6805-10. PubMed ID: 11559554
[TBL] [Abstract][Full Text] [Related]
5. Targeting of a novel fusion protein containing methioninase to the urokinase receptor to inhibit breast cancer cell migration and proliferation.
Peron K; Jones TN; Gauthier SA; Nguyen TN; Zang XP; Barriere M; Prévéraud D; Soliman CE; Harrison RG; Pento JT
Cancer Chemother Pharmacol; 2003 Oct; 52(4):270-6. PubMed ID: 12827296
[TBL] [Abstract][Full Text] [Related]
6. Purine nucleoside phosphorylase targeted by annexin v to breast cancer vasculature for enzyme prodrug therapy.
Krais JJ; De Crescenzo O; Harrison RG
PLoS One; 2013; 8(10):e76403. PubMed ID: 24098491
[TBL] [Abstract][Full Text] [Related]
7. Combination efficacy of doxorubicin and adenoviral methioninase gene therapy with prodrug selenomethionine.
Gupta A; Miki K; Xu M; Yamamoto N; Moossa AR; Hoffman RM
Anticancer Res; 2003; 23(2B):1181-8. PubMed ID: 12820369
[TBL] [Abstract][Full Text] [Related]
8. Influence of L-methioninase targeted to the urokinase receptor on the proliferation and motility of lung and prostate cancer cells.
Palwai NR; Zang XP; Harrison RG; Pento JT
Anticancer Res; 2007; 27(5A):3435-9. PubMed ID: 17970092
[TBL] [Abstract][Full Text] [Related]
9. Targeting a methioninase-containing fusion protein to breast cancer urokinase receptors inhibits growth and migration.
Zang XP; Palwai NR; Lerner MR; Brackett DJ; Pento JT; Harrison RG
Anticancer Res; 2006; 26(3A):1745-51. PubMed ID: 16827102
[TBL] [Abstract][Full Text] [Related]
10. Antitumor Synergism and Enhanced Survival with a Tumor Vasculature-Targeted Enzyme Prodrug System, Rapamycin, and Cyclophosphamide.
Krais JJ; Virani N; McKernan PH; Nguyen Q; Fung KM; Sikavitsas VI; Kurkjian C; Harrison RG
Mol Cancer Ther; 2017 Sep; 16(9):1855-1865. PubMed ID: 28522586
[TBL] [Abstract][Full Text] [Related]
11. Annexin V-targeted enzyme prodrug therapy using cytosine deaminase in combination with 5-fluorocytosine.
Van Rite BD; Harrison RG
Cancer Lett; 2011 Aug; 307(1):53-61. PubMed ID: 21546157
[TBL] [Abstract][Full Text] [Related]
12. Methioninase and selenomethionine but not Se-methylselenocysteine generate methylselenol and superoxide in an in vitro chemiluminescent assay: implications for the nutritional carcinostatic activity of selenoamino acids.
Spallholz JE; Palace VP; Reid TW
Biochem Pharmacol; 2004 Feb; 67(3):547-54. PubMed ID: 15037206
[TBL] [Abstract][Full Text] [Related]
13. Methioninase gene therapy of human cancer cells is synergistic with recombinant methioninase treatment.
Miki K; Al-Refaie W; Xu M; Jiang P; Tan Y; Bouvet M; Zhao M; Gupta A; Chishima T; Shimada H; Makuuchi M; Moossa AR; Hoffman RM
Cancer Res; 2000 May; 60(10):2696-702. PubMed ID: 10825143
[TBL] [Abstract][Full Text] [Related]
14. Design, construction, and in vitro analysis of A33scFv::CDy, a recombinant fusion protein for antibody-directed enzyme prodrug therapy in colon cancer.
Coelho V; Dernedde J; Petrausch U; Panjideh H; Fuchs H; Menzel C; Dübel S; Keilholz U; Thiel E; Deckert PM
Int J Oncol; 2007 Oct; 31(4):951-7. PubMed ID: 17786329
[TBL] [Abstract][Full Text] [Related]
15. Targeted enzyme prodrug therapy for metastatic prostate cancer - a comparative study of L-methioninase, purine nucleoside phosphorylase, and cytosine deaminase.
Guillen KP; Kurkjian C; Harrison RG
J Biomed Sci; 2014 Jul; 21(1):65. PubMed ID: 25047949
[TBL] [Abstract][Full Text] [Related]
16. Delivery of the bacterial nitroreductase gene into endothelial cells prolongs the survival of tumour-bearing mice by bystander mechanisms.
Benouchan M; Do Nascimento F; Perret GY; Colombo BM
Int J Oncol; 2006 Feb; 28(2):457-62. PubMed ID: 16391801
[TBL] [Abstract][Full Text] [Related]
17. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
[TBL] [Abstract][Full Text] [Related]
18. ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature.
Davis PD; Dougherty GJ; Blakey DC; Galbraith SM; Tozer GM; Holder AL; Naylor MA; Nolan J; Stratford MR; Chaplin DJ; Hill SA
Cancer Res; 2002 Dec; 62(24):7247-53. PubMed ID: 12499266
[TBL] [Abstract][Full Text] [Related]
19. [Effect of KDR recombinant adenovirus containing double suicide gene on proliferation of human stomach adneocarcinoma SCG7901 cells].
Li Q; Huang ZH; Yu JL; Su GQ; Li Z
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jan; 27(1):69-71, 74. PubMed ID: 17259150
[TBL] [Abstract][Full Text] [Related]
20. VP22 does not significantly enhance enzyme prodrug cancer gene therapy as a part of a VP22-HSVTk-GFP triple fusion construct.
Hakkarainen T; Wahlfors T; Meriläinen O; Loimas S; Hemminki A; Wahlfors J
J Gene Med; 2005 Jul; 7(7):898-907. PubMed ID: 15759279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
